AstraZeneca (AZN) Earns Daily Media Impact Rating of 0.25

Cornelia Mascio
Marzo 19, 2018

Weitz Investment Management Inc sold 100,000 shares as the company's stock declined 39.83% while stock markets rallied. Fisher Asset Management LLC lifted its holdings in AstraZeneca by 2.7% in the 4th quarter. The Rench Wealth Management Inc holds 39,789 shares with $2.80 million value, up from 33,560 last quarter. Wells Fargo & Company MN lifted its holdings in AstraZeneca by 7.6% in the 3rd quarter. Bank of New York Mellon Corp grew its position in AstraZeneca by 1.2% in the 4th quarter. Ameriprise Financial Inc. increased its position in AstraZeneca by 7.1% in the 3rd quarter. Zacks upgraded Aon plc (NYSE:AON) on Tuesday, August 4 to "Sell" rating. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company's stock worth $86,695,000 after buying an additional 395,699 shares during the period. The hedge fund held 26,800 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $907,000, down from 621,600 at the end of the previous reported quarter. Guggenheim downgraded the shares of AEP in report on Monday, January 9 to "Neutral" rating. Sanford C. Bernstein increased their price target on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an "outperform" rating in a report on Monday, February 5th. Leerink Swann reaffirmed a "market perform" rating and issued a $36.00 price target (up from $33.00) on shares of AstraZeneca in a research report on Thursday, January 18th. Morgan Stanley restated an "equal weight" rating and set a GBX 5,000 ($69.08) target price on shares of AstraZeneca in a research report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company's stock. The stock has a consensus rating of Hold and a consensus target price of GBX 5,199.70 ($71.84).

Shares of AstraZeneca plc (AZN) traded up $0.60 during trading hours on Friday, hitting $34.42. The stock was bought at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16). The firm has a market capitalization of $61,660.00 and a PE ratio of 2,897.02. Zeke Advsrs Ltd Liability Corp stated it has 0.06% in American Electric Power Company, Inc. AstraZeneca plc has a 52-week low of $28.43 and a 52-week high of $36.70. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since March 16, 2017 and is uptrending. The business had revenue of $5.78 billion for the quarter, compared to analysts' expectations of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. AstraZeneca's revenue was up 3.4% compared to the same quarter a year ago. AstraZeneca PLC had 617 analyst reports since July 23, 2015 according to SRatingsIntel. Stockholders of record on Friday, February 16th will be given a $0.95 dividend. This represents a dividend yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. AstraZeneca's dividend payout ratio is presently 57.81%.

TRADEMARK VIOLATION WARNING: "Capital Analysts LLC Purchases Shares of 17,171 AstraZeneca plc (AZN)" was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and global copyright and trademark laws. Cowen & Co maintained AstraZeneca PLC (NYSE:AZN) rating on Monday, October 16. The Company's marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE